Soybean Oil
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Soybean Oil: From Parenteral Nutrition to Amenorrhea
One-Sentence Summary
Soybean oil is a lipid source used in intravenous nutrition products; in South Africa it is registered as a component of Nutriflex Omega Specialized infusion. The TxGNN model predicts it may be effective for amenorrhea, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA record; the registered product is an infusion (parenteral nutrition) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.61% (model rank 2404) |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, soybean oil is a lipid emulsion component of intravenous nutrition. Its role is to supply energy and essential fatty acids rather than to act on a specific drug target.
No mechanistic link to amenorrhea has been established. The score is high, but there are no trials or publications behind it. It likely reflects proximity in the knowledge graph rather than a demonstrated biological rationale. Any connection, for example through nutritional or energy status affecting menstrual function, would be a hypothesis that this data does not test.
Clinical Trial Evidence
Currently no related clinical trials registered for amenorrhea (ClinicalTrials.gov, ICTRP; no SANCTR or PACTR entries in the Evidence Pack).
Literature Evidence
Currently no related literature available for amenorrhea.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 49/25/0065 | Nutriflex Omega Specialized | Infusion | Indication text not available in the record |
Essential Medicines List (EML) status was not assessed in the Evidence Pack.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical or literature support and no plausible mechanism. Safety information from the SAHPRA package insert is also missing, which blocks progression to safety screening.
To proceed, the following is needed:
- SAHPRA package insert warnings, contraindications and approved indication text
- Mechanism of action data (e.g., from DrugBank)
- A targeted literature search linking lipid emulsions or essential fatty acids to amenorrhea
- Confirmation that an intravenous nutrition product is a workable route for the proposed use
Other candidates: The Evidence Pack lists nine further predicted indications. Only “esophageal disease” (rank 4, L4) has any supporting studies. These are mostly perioperative nutrition in esophageal cancer surgery and physiological or animal studies of dietary fat and reflux, where fat tended to increase acid sensitivity. None shows disease treatment, so it also remains at Hold.
This report is for research reference only and does not constitute medical advice. Predicted repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.